Clinical trials: Sepsis Syndrome
Bloodstream Infection
Ethanol Locks for the Treatment of Central Venous Line Infections
Ethanol Locks as an Adjunct Treatment for Central Venous Line Infections Purpose To evaluate the effectiveness of a 70% ethanol lock solution when used as an adjunct therapy with antibiotics to treat central venous line…
- Trial name
- NCT00680459
- Testing
- 70% ethanol, heparin flush solution
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Baystate Medical Center
Candidiasis
Study Will Evaluate The Safety And Efficacy Of Anidulafungin In Patients With Candidemia Or Invasive Candidiasis
The purpose of this study is to further evaluate the safety and effectiveness of intravenous anidulafungin (Eraxis™) in patients with a diagnosis of candidemia or invasive candidiasis, which is a fungus infection of the blood or…
- Trial name
- NCT00496197
- Testing
- Eraxis (anidulafungin), Diflucan (fluconazole), Vfend (voriconazole)
- Where
- 43 sites in United States, South Korea
- Volunteers
- 282 people
- Sponsor
- Pfizer
Hypoalbuminemia
The Effect of Thalidomide in Suppression of the Systemic Inflammatory Response Syndrome in Hemodialysis Patients
Both malnutrition and inflammation are associated with death in dialysis patients and also with cardiovascular disease. The researchers are testing the idea that inflammation causes malnutrition by using a drug to suppress…
- Trial name
- ICM (NCT00529633)
- Testing
- Thalidomide, Sugar pill
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- George A. Kaysen, M.D.
Tuberculosis, HIV I Infection
Early Empiric Anti-Mycobacterium Tuberculosis Therapy for Sepsis in Sub-Saharan Africa
In sub-Saharan Africa, tuberculosis (TB) is the etiology of 25-50% of bloodstream infections (BSIs) and the leading cause of sepsis among people living with HIV.
- Conditions
- Tuberculosis, HIV I Infection, Sepsis
- Trial name
- ATLAS (NCT04618198)
- Testing
- Immediate anti-TB therapy, Sepsis-specific dose anti-TB therapy
- Where
- 2 sites in Tanzania, Uganda
- Volunteers
- 437 people
- Sponsor
- University of Virginia
Septic Shock
Crystalloid Liberal or Vasopressors Early Resuscitation in Sepsis
Multicenter, prospective, phase 3 randomized non-blinded interventional trial of fluid treatment strategies in the first 24 hours for patients with sepsis-induced hypotension.
- Trial name
- CLOVERS (NCT03434028)
- Testing
- Early Vasopressors, Early Fluids
- Where
- 50 sites in United States
- Volunteers
- 1,563 people
- Sponsor
- Massachusetts General Hospital
Sepsis
Changes in Exhaled 13CO2/12CO2 Breath Delta Value as an Early Indicator of Infection in ICU Patients
Carbon-12 and carbon-13 are naturally-abundant isotopes in exhaled breath carbon dioxide. The ratio of carbon-13 to carbon-12 in exhaled breath is known as the breath delta value (BDV).
- Trial name
- NCT02327130
- Testing
- Isomark Canary™
- Where
- 6 sites in United States
- Volunteers
- 32 people
- Sponsor
- Isomark, LLC
Septic Shock
Intravenous AII for the Treatment of Severe Hypotension in High Output Shock: A Pilot Study
The investigators propose a dose finding study to determine the feasibility of Angiotensin II (AII) to increase mean arterial pressure in high-output shock.
- Trial name
- ATHOS (NCT01393782)
- Testing
- Angiotensin II
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- George Washington University
Sepsis, Septic Shock
Vitamin C & Thiamine to Treat Sepsis and Septic Shock
Investigators propose to investigate the use of IV vitamins B1 and C in a randomized, double-blinded, prospective trial to determine if these medications decrease mortality rates in patients with severe sepsis or septic shock.
- Trial name
- NCT03592277
- Testing
- Vitamin C, Vitamin B1
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Trinity Health Of New England
Acute Kidney Injury Due to Sepsis
(Revival) Study to Investigate the Efficacy and Safety of Alkaline Phosphatase in Patients With Sepsis-Associated AKI
Clinical phase 3 study to investigate the effect of recAP on 28 day mortality in patients admitted to the ICU with acute kidney injury that is caused by sepsis. The study has three distinct SA-AKI trial populations: 1.
- Trial name
- NCT04411472
- Testing
- Recombinant human alkaline phosphatase
- Where
- 122 sites in United States, Australia and 13 more
- Volunteers
- 676 people
- Sponsor
- AM-Pharma
COVID-19
Assessment of Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT)
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib in the treatment of participants with COVID-19-associated Acute Respiratory Distress Syndrome (ARDS) who require mechanical ventilation.
- Trial name
- NCT04377620
- Testing
- Ruxolitinib
- Where
- 36 sites in United States, Russia
- Volunteers
- 211 people
- Sponsor
- Incyte Corporation
Clostridia Difficile Colitis, Clostridium; Sepsis
Comparing the Effectiveness of IV Bezlotoxumab Versus Placebo in Decreasing Morbidity and Mortality in Patients With Fulminant C. Diff Requiring Surgery.
A new medication, Bezlotoxumab, has been approved for treatment of recurrent Clostridium difficile diarrhea by the U.S. Food and Drug Administration. The way this new medication works, is by binding the toxin produced by C.
- Trial name
- NCT03756454
- Testing
- Bezlotoxumab, Normal Saline
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Ohio State University
Invasive Candidiasis
β-D-Glucan (BDG) Surveillance With Preemptive Anidulafungin vs. Standard Care for Invasive Candidiasis in Surgical Intensive Care Unit (SICU) Patients
This is a single center, prospective, open label assessment of β-D-glucan surveillance with preemptive anidulafungin therapy versus standard care for the prevention of invasive candidiasis in at-risk surgical intensive care unit…
- Trial name
- NCT00672841
- Testing
- Preemptive Therapy with Anidulafungin, Empiric antifungal therapy based on physician discretion.
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- Duke University
Catecholamine-resistant Hypotension (CRH), Distributive Shock
A Phase 3 Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension
This is a Phase 3, double-blind, randomized study of LJPC-501 (angiotensin II) in adult patients diagnosed with catecholamine-resistant hypotension (CRH) conducted in multiple centers globally.
- Conditions
- Catecholamine-resistant Hypotension (CRH), Distributive Shock, High Output Shock, Sepsis
- Trial name
- ATHOS-3 (NCT02338843)
- Testing
- LJPC-501
- Where
- 115 sites in United States, Australia and 8 more
- Volunteers
- 344 people
- Sponsor
- La Jolla Pharmaceutical Company
Intra-Abdominal Infections, Intestinal Obstruction
Capillary Leak Index as a Prognostic Indicator for Post-Operative Abdominal Sepsis in Critically Ill Patients
In this study the investigators going to evaluate the "CLI" as an early prognostic indicator for post-operative abdominal sepsis in critically ill patients.
- Conditions
- Intra-Abdominal Infections, Intestinal Obstruction, Appendicitis Acute, Perforated Viscus
- Trial name
- CLI (NCT06901544)
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Ain Shams University
Acute Respiratory Distress Syndrome, ARDS (Moderate or Severe)
Multiple Dosing of Mesenchymal Stromal Cells in Patients With ARDS (COVID-19)
This is a multi-center, randomized, placebo controlled, interventional phase 2A trial to evaluate the safety profile and potential efficacy of multi-dosing of mesenchymal stromal cells (MSC) for patients with SARS-CoV-2…
- Conditions
- Acute Respiratory Distress Syndrome, ARDS (Moderate or Severe), COVID-19 Pneumonia
- Trial name
- NCT04466098
- Testing
- Mesenchymal stromal cells
- Where
- 2 sites in United States
- Volunteers
- 8 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Bloodstream Infection, Sepsis Bacterial
Effect of Direct-from-blood Bacterial Testing on Antibiotic Administration and Clinical Outcomes
Bacterial blood stream infections are common and life-threatening. Bloodstream infections have historically been identified using blood cultures, which often take 24-72 hours to result and are imperfectly sensitive.
- Conditions
- Bloodstream Infection, Sepsis Bacterial, MRSA Bacteremia, Vancomycin
- Trial name
- NCT06069206
- Testing
- T2Bacteria® Panel (direct-from-blood testing), Usual Care
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- Vanderbilt University Medical Center
Candidemia
Anidulafungin In Treatment Of Candidemia In Asian Subjects
The purpose of this study is to determine whether or not the Investigational Study Drug anidulafungin is safe and effective in the treatment of a fungal infection, candidemia, in Asian subjects.
- Trial name
- NCT00537329
- Testing
- Anidulafungin
- Where
- 13 sites in India, Philippines and 2 more
- Volunteers
- 43 people
- Sponsor
- Pfizer
Sepsis
The CRISIS Prevention Study
Despite strict hand washing, sterile technique, and antibiotic-coated catheters, nosocomial infection and sepsis remain the leading acquired causes of morbidity and mortality in critically ill children.
- Trial name
- CRISIS (NCT00395161)
- Testing
- Metoclopramide, Zinc, Glutamine
- Where
- 7 sites in United States
- Volunteers
- 293 people
- Sponsor
- Michael Dean
Septic Shock
Treatment of Patients With Early Septic Shock and Bio-Adrenomedullin(ADM) Concentration > 70 pg/ml With ADRECIZUMAB
This is a double-blind, placebo-controlled, randomized, multicenter proof of concept and dose-finding phase II study using two doses of ADRECIZUMAB in patients with early septic shock and a bio-ADM plasma concentration at…
- Trial name
- AdrenOSS-2 (NCT03085758)
- Testing
- Adrecizumab
- Where
- 30 sites in Belgium, France and 2 more
- Volunteers
- 301 people
- Sponsor
- Adrenomed AG
Candidemia
Negative Beta Glucan in ICU Patients
This is a prospective study aimed at testing a strategy of early initiation of an antifungal agent to patients admitted to intensive care units (ICUs) at risk for invasive candidiasis.
- Trial name
- NCT01734525
- Testing
- Anidulafungin
- Where
- Brazil
- Volunteers
- 85 people
- Sponsor
- Universidade Federal do Rio de Janeiro